J. Stoehlmacher

发表

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

S. Groshen, H. Lenz, K. Danenberg, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity.

H. Lenz, R. Ladner, Mimi C. Yu, 2003, Cancer research.

Tailoring chemotherapy in advanced colorectal cancer.

H. Lenz, J. Stoehlmacher, David J. Park, 2003, Current opinion in pharmacology.

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.

A. Hinke, A. Tannapfel, T. Trarbach, 2015, The Lancet. Oncology.

Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation.

D. Aust, G. Baretton, G. Ehninger, 2008, Cancer letters.

Pharmacogenetic aspects in treatment of colorectal cancer--an update.

H. Lenz, J. Stoehlmacher, E. Goekkurt, 2003, Pharmacogenomics.

Implications of Genetic Testing in the Management of Colorectal Cancer

H. Lenz, J. Stoehlmacher, 2003, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels.

S. Groshen, H. Lenz, R. Ladner, 2004, Pharmacogenetics.

ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.

S. Groshen, H. Lenz, Wu Zhang, 2003, Clinical advances in hematology & oncology : H&O.

Polymorphisms in Genes of Drug Targets and Metabolism and in DNA Repair

H. Lenz, J. Stoehlmacher, S. Iqbal, 2004 .

A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.

S. Groshen, H. Lenz, J. Stoehlmacher, 2001, Anticancer research.

Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.

S. Groshen, H. Lenz, Dongyun Yang, 2005, Clinical colorectal cancer.

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.

A. Hinke, H. Schmoll, A. Tannapfel, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular analysis of the polymorphisms of thymidylate synthase on cell‐free circulating DNA in blood of patients with advanced colorectal carcinoma

D. Aust, K. Pantel, J. Stoehlmacher, 2010, International journal of cancer.

A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP)

S. Hollerbach, R. Hofheinz, J. Hartmann, 2006 .

Pharmacogenetics of Extraordinary Responses to 5-FU/Cisplatin Chemotherapy in Advanced Gastric Cancer – Report of 2 Cases

D. Hossfeld, J. Stoehlmacher, S. Al-Batran, 2005, Oncology Research and Treatment.

S. Hollerbach, R. Hofheinz, J. Hartmann, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO.

M. Egger, J. Trojan, W. Schmiegel, 2015 .

Induction of Toll-like receptor 2 and 4 expression on CD4+ and CD8+ T cells in G-CSF-mobilized unrelated peripheral blood stem cell grafts during leukapheresis: impact on patient outcome

G. Ehninger, J. Stoehlmacher, U. Platzbecker, 2008, Leukemia.

Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

J. Hartmann, G. Ehninger, J. Stoehlmacher, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Prediction of efficacy and side effects of chemotherapy in colorectal cancer.

J. Stoehlmacher, 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Detection and Monitoring of Cell‐Free DNA in Blood of Patients with Colorectal Cancer

K. Pantel, J. Stoehlmacher, H. Schwarzenbach, 2008, Annals of the New York Academy of Sciences.

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.

R. Hofheinz, J. Hartmann, J. Stoehlmacher, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.

C. Bokemeyer, S. Hollerbach, R. Hofheinz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) – novel predictors for response and survival in gastric cancer patients

C. Wittmer, D. Hossfeld, J. Stoehlmacher, 2005, British Journal of Cancer.

Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

S. Groshen, S. Ingles, H. Lenz, 2001, The Pharmacogenomics Journal.

Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer.

S. Groshen, H. Lenz, Wu Zhang, 2002, Journal of the National Cancer Institute.

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.

J. Weitz, F. Lordick, T. Gruenberger, 2010, The Lancet. Oncology.

dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer.

S. Groshen, H. Lenz, R. Ladner, 2000, Cancer research.

A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.

S. Groshen, H. Lenz, W. Zhang, 2001, Cancer research.

Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.

C. Bokemeyer, J. Hartmann, G. Schuch, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

S. Groshen, H. Lenz, W. Zhang, 2004, British Journal of Cancer.

CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status.

C. Schumann, J. Stoehlmacher, D. Behringer, 2015, Clinical lung cancer.

Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation.

N. Kröger, S. Iacobelli, A. Zander, 2007, Anticancer research.

Effect of cytokine genotypes on the hepatitis B virus‐hepatocellular carcinoma association

Jian-Min Yuan, Mimi C. Yu, J. Stoehlmacher, 2005, Cancer.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

M. Egger, V. Heinemann, J. Trojan, 2019, The Lancet.

Cyclooxygenase-2 inhibitors in colorectal cancer.

H. Lenz, J. Stoehlmacher, 2003, Seminars in oncology.

Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial

M. Egger, U. Martens, S. Post, 2017, JAMA oncology.

Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical trial.

D. Atanackovic, R. Bals, F. Mayer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modified FOLFOX in combination with docetaxel for patients with metastatic adenocarcinoma of the stomach or gastroesophageal junction: A multicenter phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

R. Hofheinz, J. Hartmann, J. Stoehlmacher, 2007 .

Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.

A. Kiani, G. Ehninger, J. Stoehlmacher, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

to 5-Fluorouracil in Colorectal Cancer Neoplastic Tissues : Association with Survival and Response dUTP Nucleotidohydrolase Isoform Expression in Normal and Updated

S. Groshen, H. Lenz, R. Ladner, 2000 .

The impact of genomics and proteomics in the clinic: functional genetic polymorphisms and their value in response and toxicity prediction in solid tumours.

J. Stoehlmacher, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer : the AIO-FLOT 3 trial

M. Egger, U. Martens, S. Post, 2017 .

Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer

S. Groshen, H. Lenz, Wu Zhang, 2002, International Journal of Colorectal Disease.

Tailored Chemotherapy for Colorectal Cancer: A New Approach to Therapy

H. Lenz, J. Stoehlmacher, S. Iqbal, 2004, Cancer investigation.

Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients

E. Wardelmann, F. Heidel, T. Fischer, 2007, Gastric Cancer.

Pattern of progression and its impact on outcome in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: A retrospective multicenter long-term follow-up study.

E. Wardelmann, F. Heidel, T. Fischer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The -9Ala/-9Val polymorphism in the mitochondrial targeting sequence of the manganese superoxide dismutase gene (MnSOD) is associated with age among Hispanics with colorectal carcinoma.

S. Ingles, H. Lenz, Wu Zhang, 2002, Oncology reports.

Dose escalating study of 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy of patients with metastatic colorectal cancer.

G. Folprecht, T. Trarbach, G. Ehninger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thymidylate synthase polymorphisms and immunohistochemistry in non-small cell lung cancer.

J. Schirren, G. Ehninger, J. Stoehlmacher, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.

A. Kiani, G. Ehninger, J. Stoehlmacher, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reply: Is thymidylate synthase a reliable predictor for response and survival during hepatic arterial infusion for hepatic metastasis from colorectal cancer

J. Stoehlmacher, E. Goekkurt, 2006, British Journal of Cancer.

Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial

A. Hinke, H. Schmoll, A. Tannapfel, 2016 .

Polymorphism of the Thymidylate Synthase Gene Abolishes USF-1 Binding and Alters Transcriptional Activity

H. Lenz, R. Ladner, Mimi C. Yu, 2022 .

J. Stoehlmacher, S. Al-Batran, E. Goekkurt, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Associations between the EGFR status as well as KRAS mutations and clinical outcome in colorectal cancer (CRC) patients (pts) treated with erlotinib monotherapy in 2nd or 3rd line—A study of the Arbeitsgemeinschaft Internistische

S. Kubicka, F. Lordick, N. Niederle, 2008 .

Preliminary pharmacogenetic evaluation of toxicity data in the prospective multicentre EORTC trial 40015 in metastatic colorectal cancer (CRC).

D. Aust, E. Van Cutsem, J. Hartmann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.